TNF and Guillain-Barre syndrome: APOA1 can also bind and neutralize lipopolysaccharide (LPS), a Gram-negative product, leading to reduced activation of TLR4 and decreased release of TNF-α and IL-1β, thereby alleviating clinical symptoms in GBS patients (10).